Barriers and Motivations for Women to Participate in Cardiovascular Trials
Barriers and Motivations for Women to Participate in Cardiovascular Trials
复制标题
DOI：
10.1016/s1701-2163(16)32802-x
复制
发表时间：
2008-04-01
影响因子：
1.8
通讯作者：
Stewart, Donna E.
中科院分区：
文献类型：
--
作者：
Cheung, Angela M.;Lee, Yuna;Stewart, Donna E.
背景：心血管疾病是加拿大妇女死亡的主要原因之一。然而，与心血管疾病的患病率相比，被招募参加心血管临床试验的女性人数仍然很低。为了确定为什么招募女性参加心血管试验仍然存在问题，我们前瞻性地调查了雷洛昔芬用于心脏(RUTH)研究中联系的女性的障碍和动机。方法：对270名绝经后女性进行了调查。无论研究资格如何，女性都被要求以开放式单一问题的形式评论她们参与或不参与心血管试验的原因。结果：54%的受访女性表示不会参与临床研究，46%的女性表示会参与。据报道，参与心血管临床试验的动机包括个人健康利益(82.2%)、对研究的兴趣(44.1%)和造福社会的可能性(29.1%)。拒绝参与的原因包括个人疾病(24.8%)、交通问题(17.9%)、不愿增加用药(15.2%)和担心不良健康影响(13.1%)。结论：根据我们的绝经后妇女队列报告，进入与心血管疾病相关的随机对照试验的主要障碍是认为参与会增加健康和时间的负担。我们的经验表明，研究人员需要教育女性了解临床试验的重要性，他们还需要为交通等障碍提供切实可行的解决方案。
Background: Cardiovascular disease is one of the major causes of mortality in Canadian women. However, the number of women recruited into cardiovascular clinical trials continues to be low relative to the prevalence of cardiovascular disease. To determine why the recruitment of women into cardiovascular trials continues to be problematic, we prospectively examined the barriers and motivations of women contacted for the Raloxifene Use for The Heart (RUTH) study.Methods: Two hundred seventy postmenopausal women were surveyed. Regardless of study eligibility, women were asked to comment on their reasons for participating or not participating in cardiovascular trials in an open-ended single question format. All answers were recorded and grouped accordingly.Results: Fifty-four percent of women surveyed indicated they would not participate in clinical research, and 46% indicated that they would. Motivations reported for participating in a cardiovascular clinical trial included personal health benefits (82.2%), interest in research (44.1%), and the possibility of benefiting society (29.1%). Reasons for declining participation included personal illness (24.8%), transportation issues (17.9%), reluctance to increase medication (15.2%), and concern about adverse health effects (13.1%).Conclusion: As reported by our cohort of postmenopausal women, the major barrier to entering a randomized controlled trial related to cardiovascular disease was the perception that participation would present an increased burden on health and time. Our experience suggests that researchers need to educate women on the importance of clinical trials and that they also need to provide practical solutions to barriers such as transportation.